Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy announces promising initial Phase 2 results for their BEXMAB trial, showing a 79% objective response rate in myelodysplastic syndrome (MDS) patients previously unresponsive to HMA therapy, with a median overall survival rate significantly higher than historical standards. The company’s leading drug, bexmarilimab, demonstrates potential as a new treatment option for r/r MDS, a condition with limited existing treatments and a high unmet medical need. Faron is committed to accelerating the development of bexmarilimab to address this urgent clinical gap.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
